Imidazo[1,2-a]quinazolines as novel, potent EGFR-TK inhibitors: Design, synthesis, bioactivity evaluation, and in silico studies.

[1]  Melissa F. Adasme,et al.  PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA , 2021, Nucleic Acids Res..

[2]  A. Foroumadi,et al.  Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy. , 2021, European journal of medicinal chemistry.

[3]  Bin Zhang,et al.  Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. , 2021, European journal of medicinal chemistry.

[4]  J. Tuszynski,et al.  An insight into the anticancer potential of carbamates and thiocarbamates of 10-demethoxy-10-methylaminocolchicine. , 2021, European journal of medicinal chemistry.

[5]  Kahksha,et al.  Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019). , 2020, European journal of medicinal chemistry.

[6]  P. Colas,et al.  Kinase-Based Screening of Marine Natural Extracts Leads to the Identification of a Cytotoxic High Molecular Weight Metabolite from the Mediterranean Sponge Crambe tailliezi , 2019, Marine drugs.

[7]  N. Girard.  Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates. , 2019, Future oncology.

[8]  R. Roskoski.  Properties of FDA-approved small molecule protein kinase inhibitors. , 2019, Pharmacological research.

[9]  Debasis Das,et al.  Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. , 2019, European journal of medicinal chemistry.

[10]  R. Esmaeili,et al.  6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic agents: Design, synthesis and structure-activity relationship studies. , 2019, European journal of medicinal chemistry.

[11]  Matthew G. Donahue,et al.  Quinolines from the cyclocondensation of isatoic anhydride with ethyl acetoacetate: preparation of ethyl 4-hydroxy-2-methylquinoline-3-carboxylate and derivatives , 2018, Beilstein journal of organic chemistry.

[12]  J. Smaill,et al.  Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry , 2018, Medicinal research reviews.

[13]  F. Halaweish,et al.  Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells. , 2018, European journal of medicinal chemistry.

[14]  Zachary D Schrank,et al.  Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance , 2018, Cancers.

[15]  Guang Liang,et al.  Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer. , 2017, Journal of medicinal chemistry.

[16]  J. Contreras-Garcı́a,et al.  Accurately extracting the signature of intermolecular interactions present in the NCI plot of the reduced density gradient versus electron density. , 2017, Physical chemistry chemical physics : PCCP.

[17]  Harun Patel,et al.  Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. , 2017, European journal of medicinal chemistry.

[18]  Tang Yuting,et al.  Synthesis and antitumor evaluation of 5-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(tert-butyl)-N-arylthiazol-2-amines , 2016 .

[19]  D. Turner,et al.  Electrostatic Potential Change in a Paired Epitope: A Novel Explanation for Bw4 Antibodies in Patients With B13 (Bw4) Antigens. , 2016, Transplantation.

[20]  L. Sequist,et al.  Update to Rociletinib Data with the RECIST Confirmed Response Rate. , 2016, The New England journal of medicine.

[21]  J. Cicenas.  The Aurora kinase inhibitors in cancer research and therapy , 2016, Journal of Cancer Research and Clinical Oncology.

[22]  K. Varnäs,et al.  Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. , 2015, Journal of medicinal chemistry.

[23]  N. Jain,et al.  Synthesis and antiproliferative activity of imidazo[1,2-a]pyrimidine Mannich bases. , 2015, European journal of medicinal chemistry.

[24]  Wei Huang,et al.  A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. , 2014, Journal of medicinal chemistry.

[25]  U. Nonstad,et al.  Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor. , 2014, European journal of medicinal chemistry.

[26]  K. Abouzid,et al.  Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors. , 2013, European journal of medicinal chemistry.

[27]  J. Christensen,et al.  Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib , 2012, Molecular Cancer Therapeutics.

[28]  Tian Lu,et al.  Multiwfn: A multifunctional wavefunction analyzer , 2012, J. Comput. Chem..

[29]  Eric F. Johnson,et al.  Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions. , 2011, Bioorganic & medicinal chemistry letters.

[30]  Raed A. Al‐Qawasmeh,et al.  Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents. , 2010, European journal of medicinal chemistry.

[31]  A. Kamal,et al.  Design, synthesis and biological evaluation of imidazopyridine/pyrimidine-chalcone derivatives as potential anticancer agents , 2010 .

[32]  S. Goueli,et al.  ADP-Glo: A Bioluminescent and homogeneous ADP monitoring assay for kinases. , 2009, Assay and drug development technologies.

[33]  P. Groundwater,et al.  An overview of cancer treatments , 2009 .

[34]  J. Hyun,et al.  Apoptosis inducing activity of fucoidan in HCT-15 colon carcinoma cells. , 2009, Biological & pharmaceutical bulletin.

[35]  Trent E Balius,et al.  Quantitative prediction of fold resistance for inhibitors of EGFR. , 2009, Biochemistry.

[36]  F. Shepherd,et al.  The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement , 2009, Current oncology.

[37]  M. Meyerson,et al.  BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.

[38]  E. De Clercq,et al.  Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II. , 2007, Bioorganic & medicinal chemistry.

[39]  Jeffrey Jie-Lou Liao,et al.  Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. , 2007, Journal of medicinal chemistry.

[40]  A. Cavalli,et al.  Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects. , 2006, Journal of medicinal chemistry.

[41]  H. Cottam,et al.  Inhibitors of apoptosis in lymphocytes: synthesis and biological evaluation of compounds related to pifithrin-alpha. , 2005, Journal of medicinal chemistry.

[42]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[43]  P. Bonomi.  Erlotinib: a new therapeutic approach for non-small cell lung cancer , 2003, Expert opinion on investigational drugs.

[44]  J. Siekierka,et al.  Imidazopyrimidines, potent inhibitors of p38 MAP kinase. , 2003, Bioorganic & medicinal chemistry letters.

[45]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[46]  A. Wells.  EGF receptor. , 1999, The international journal of biochemistry & cell biology.

[47]  J. Baselga,et al.  PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  G. Cooper,et al.  Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1 , 1997, Molecular and cellular biology.

[49]  Mark S. Gordon,et al.  General atomic and molecular electronic structure system , 1993, J. Comput. Chem..

[50]  W. Spitzer,et al.  Imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyrazines: the role of nitrogen position in inotropic activity. , 1988, Journal of medicinal chemistry.

[51]  M. Fisher,et al.  Imidazo(1,2-a)pyridine anthelmintic and antifungal agents. , 1972, Journal of medicinal chemistry.

[52]  A. Olivi,et al.  Derivatives of imidazole. II. Synthesis and reactions of imidazo[1,2-alpha]pyrimidines and other bi- and tricyclic imidazo derivatives with analgesic, antiinflammatory, antipyretic, and anticonvulsant activity. , 1966, Journal of medicinal chemistry.

[53]  S. Cohen,et al.  Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. , 1962, The Journal of biological chemistry.